China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook

WuXi AppTec

26/10/2026 09:15

Overview
China pharma R&D services firm's nine-month revenue rose 39% year-over-year
Adjusted non-IFRS net profit attributable to owners increased sharply year-over-year
Company raised full-year revenue and adjusted free cash flow guidance for 2026

Outlook
WuXi AppTec raises 2026 total revenue guidance to RMB61.0-61.9 bln from RMB58.5-60.5 bln
Company now expects 2026 continuing operations revenue to grow 40%-42% YoY
WuXi AppTec raises 2026 adjusted free cash flow forecast to RMB14.5-15.5 bln from RMB13.5-14.5 bln

Result Drivers
CHEMISTRY SEGMENT - Co said strong growth in WuXi Chemistry was driven by pipeline progression to late stages and ramp-up of new capacity
TIDES MODALITIES - Co said rapid growth in TIDES business was supported by increased customer and molecule counts
DRUG SAFETY SERVICES - Co said drug safety evaluation services contributed to WuXi Testing segment growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
9M Revenue
 
RMB 45.54 bln
 
9M Net Income Attributable
 
RMB 19.16 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for WuXi AppTec Co., Ltd. is CNY185.25, about 26.9% above its October 26 closing price of CNY146.00
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
Oct 23 - Bristol Myers, SystImmune breast cancer drug cuts progression risk in study
Oct 23 - Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients
Oct 26 - China's yuan climbs to fresh 4-year high ahead of key policy meetings

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)